Group 1 - The core focus is on strengthening industrial chains and attracting investment through project development, with a clear strategy to identify and address gaps in the industry [1][13][14] - In the first three quarters, a total of 720 projects were signed through provincial platforms, with actual investment from external industrial projects increasing by 3.3% year-on-year [1][13] - The establishment of 777 new foreign-invested enterprises and the increase in capital from 155 existing foreign companies highlight the efforts to stabilize foreign investment [1][13] Group 2 - Major brand events such as the Western China International Fair and investment promotion conferences have been organized to enhance the province's openness and investment environment [2][10] - A total of over 40 specialized promotional activities have been conducted, focusing on precise and targeted investment attraction rather than large-scale events [9][10] - The province has implemented a project lifecycle service mechanism to address bottlenecks and improve the efficiency of project execution [2][10] Group 3 - The focus on specific industrial tracks has led to the organization of investment promotion meetings tailored to sectors like photovoltaic energy, low-altitude economy, and health care [7][9] - The aluminum industry has seen significant activity, with the signing of 41 projects worth 232.3 billion yuan during a recent conference, emphasizing the importance of building a complete industrial chain [8][9] - The integration of financial services with industry-specific needs has been highlighted, particularly in the cultural tourism sector, to create a comprehensive service ecosystem [10][11] Group 4 - The provincial economic cooperation system is actively working to refine the industrial map and identify key sub-chains for targeted investment attraction [14][15] - The emphasis on collaboration between primary and secondary enterprises within the industrial chain aims to enhance resilience and security in supply chains [13][14] - Future plans include a three-year action plan for project attraction focused on strengthening and extending key sub-chains, transitioning from single project investments to a more integrated approach [15]

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2]. Core Insights - The report emphasizes the potential of KT-621 (STAT6 PROTAC) as an oral alternative to Dupilumab (Dupi), highlighting its efficacy and safety in treating atopic dermatitis (AD) [6][15]. - The report suggests that the demand for oral therapies in the autoimmune sector is expected to grow, driven by the need for new molecular entities (NME) that can match existing therapies in efficacy and safety [6][25]. - The report identifies key companies to watch in the domestic market, including 康诺亚, 先声药业, 益方生物, and 海思科, which are positioned to benefit from this trend [26]. Summary by Sections Industry Overview - The closing index for the industry is 8280.55, with a 52-week high of 9323.49 and a low of 6764.34 [2]. Market Performance - In the week of December 8 to December 12, 2025, the A-share pharmaceutical and biotechnology sector fell by 1.04%, underperforming the CSI 300 index by 0.96 percentage points and the ChiNext index by 3.78 percentage points [7][45]. - The report ranks the pharmaceutical sector 17th among 31 first-level sub-industries in terms of weekly performance [7]. Recent Trends 1. **Innovative Drugs**: The report expresses optimism about the long-term trends in innovative drugs, noting that China's innovative drug industry has developed the capability to compete globally. The report highlights ongoing collaborations with multinational corporations (MNCs) as a sign of recognition of domestic companies' R&D capabilities [8][29]. 2. **Medical Devices**: The report indicates a slight decrease in funding for innovative drugs, with some capital shifting towards the medical device sector, which is expected to see improved performance [8][37]. 3. **Traditional Chinese Medicine**: The report notes that traditional Chinese medicine is under pressure but highlights potential benefits from basic drug policies and innovation [9][40]. Investment Recommendations - The report recommends focusing on companies that are well-positioned in the innovative drug space, such as 信达生物, 康方生物, and 科伦博泰生物, among others [29][30]. - For the medical device sector, companies like 迈瑞医疗 and 开立医疗 are highlighted as beneficiaries of the improving market conditions [37][38]. - In the traditional Chinese medicine sector, companies like 佐力药业 and 方盛制药 are noted for their potential to benefit from policy changes and market recovery [40][41]. Clinical Data Insights - KT-621's phase 1b clinical trial data shows comparable efficacy to Dupi, with significant reductions in biomarkers and clinical scores for atopic dermatitis [18][24]. - The safety profile of KT-621 is reported to be excellent, with no serious adverse events noted during the trial [25]. Conclusion - The report concludes that KT-621 has the potential to become a leading oral therapy in the autoimmune market, with strong backing from clinical data and market trends [25][26].

Group 1: Macroeconomic Insights - The Federal Reserve is likely to enter an "observation period" after the recent interest rate cut, amid conflicting inflation and employment indicators [2][3] - The Central Economic Work Conference emphasizes a moderate expansion policy and high-quality development, with a more positive stance on real estate policies [3][4] - Domestic macro data shows active resident travel but subdued industrial production, with a focus on the impact of real estate policies and fiscal measures for the upcoming year [3][4] Group 2: Investment Strategies - A bottom-up approach is recommended for positioning in the spring market, focusing on five structural themes, including AI computing power and lithium battery storage [3][4] - The market sentiment in Hong Kong remains pessimistic, with potential catalysts for future rallies identified, such as RMB appreciation and domestic technological advancements [4] - Investors are advised to adopt a trading mindset in convertible bonds, focusing on short-term opportunities while being cautious of credit events [7][8] Group 3: Sector-Specific Developments - The Hong Kong Stock Exchange launched the HKEX Technology 100 Index, which has outperformed the Hang Seng Tech Index, indicating a broader coverage of tech-related sectors [5] - The energy sector is shifting focus from supply to demand research, with AI infrastructure driving significant growth in electricity demand [12] - The investment focus in the solid-state battery equipment sector is shifting towards production engineering, with expectations for significant growth in the coming years [13]

Summary of the Conference Call on the Pharmaceutical Industry Industry Overview - **Industry**: Pharmaceutical Industry - **Rating**: Leading - **2026 Outlook**: Value recovery, upward trend continues, selective layout amidst differentiation [1] Core Insights and Arguments - **Industry Trends**: - The industry is expected to maintain a relatively fast growth rate despite tightening drug regulations and increasing challenges in new drug development in the U.S. [2] - The integration trend within the industry is just beginning, with leading players in high-growth segments showing strong long-term certainty [2] - **Private Hospitals**: - High-quality private hospital targets are recommended as cost control pressures ease and outdated capacities are eliminated, allowing for a return to faster growth [3] - Recommended stocks include Gushengtang and Haijia Medical, which are expected to rebound in the short term and have clear long-term expansion paths [3] - **Valuation Summary**: - A detailed table of various pharmaceutical companies with their stock codes, ratings, target prices, closing prices, earnings per share (EPS), price-to-earnings ratios (P/E), and other financial metrics is provided [4] Important but Overlooked Content - **Market Performance**: - The MSCI China Pharmaceutical Index increased by 62.0% year-to-date, outperforming the MSCI China Index by 31.8 percentage points [10] - The pharmaceutical sector has officially entered a rebound phase, with significant performance differentiation among sub-sectors [10] - **Policy Environment**: - The policy environment is improving, with the government supporting innovative drug development and introducing commercial insurance funds to supplement the medical insurance directory [11] - The latest round of medical insurance negotiations has successfully included 127 drugs outside the directory, indicating a shift towards a more balanced pricing strategy [11] - **Innovation and R&D**: - The industry is witnessing a positive cycle of R&D breakthroughs and global licensing, with many companies entering a "R&D investment - clinical breakthrough - global licensing" cycle [11] - As of September 2025, Chinese pharmaceutical companies have completed 103 overseas transactions, exceeding 77% of the total transaction amount for 2024 [11] - **Financial Performance**: - The overall revenue of the A-share pharmaceutical sector showed a marginal recovery in Q3 2025, with a 0.7% year-on-year increase, indicating strong operational resilience [17] - The sector's earnings growth expectations are improving, with leading companies showing rapid recovery in performance [11][20] - **Investment Opportunities**: - The report emphasizes two main investment lines: focusing on innovative companies with strong differentiation and product export potential, and capitalizing on the recovery of valuation multiples and earnings growth [32][34] - Specific recommendations include companies like Sanofi Pharmaceutical, Deqi Pharmaceutical, and Baiji Shenzhou, which have rich catalysts and are still undervalued [35] - **AI in Healthcare**: - The application of AI in healthcare is highlighted as a new theme for industry innovation, with significant market expansion potential [33] - **Future Outlook**: - The pharmaceutical industry is expected to maintain a stable upward trend in 2026, with a focus on fundamental performance and valuation [30] - The introduction of the commercial insurance innovative drug directory and ongoing policy reforms are anticipated to further enhance market sentiment and fundamental expectations [37]

www.hczq.com 证券研究报告 | 医药生物 | 2025年12月13日 华创医药投资观点&研究专题周周谈 · 第154期 2025Q3实体药店市场分析 本周专题联系人：高初蕾 华创医药团队： | 首席分析师 | 郑辰 | | 执业编号：S0360520110002 | 邮箱：zhengchen@hcyjs.com | | --- | --- | --- | --- | --- | | 联席首席分析师 | | 刘浩 | 执业编号：S0360520120002 | 邮箱：liuhao@hcyjs.com | | 医疗器械组组长 | | 李婵娟 | 执业编号：S0360520110004 | 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长 | | 高初蕾 | 执业编号：S0360524070002 | 邮箱：gaochulei@hcyjs.com | | 分析师 | 王宏雨 | | 执业编号：S0360523080006 | 邮箱：wanghongyu@hcyjs.com | | 分析师 | 朱珂琛 | | 执业编号：S0360524070007 | 邮箱：zhukechen@h ...

Group 1 - The core viewpoint is that the US economy is expected to maintain moderate growth next year, supported by factors such as Federal Reserve interest rate cuts and AI investments, while remaining strategically bullish on US stocks but cautious of structural differentiation and short-term risks in Q1 [1] - For the Hong Kong stock market outlook, it is anticipated that the market will shift from valuation-driven to profit growth-driven, with valuation expansion likely to weaken but liquidity remaining supportive [1] - The combination of profit-driven growth and liquidity support is expected to emerge by 2026, with new supply creating new demand as a new driving force for the Hong Kong stock market [1] Group 2 - The technology sector in the US stock market is expected to become more rational, with AI remaining a key driver, and the regulatory environment being favorable for mergers and acquisitions [1] - The AI advancements are projected to continue driving revenue and valuation recovery in the Chinese internet sector's cloud business [1] - The domestic pharmaceutical and innovative drug sectors are likely to benefit from a resurgence in mergers and acquisitions by large multinational pharmaceutical companies, as well as an increase in BD transactions [1] Group 3 - The automotive industry is expected to see flat or slightly declining sales next year, with current market sentiment being sufficiently pessimistic, presenting an opportunity to gradually accumulate stocks of companies with high earnings growth certainty [2] - The consumption sector's recovery remains uneven, suggesting a strategy of "anchoring on earnings while leveraging growth" for investment [2] - The education sector is viewed positively for its resilient growth and expansion opportunities [2] Group 4 - Recommended stocks for Q1 next year include: Alphabet (GOOGL.US), Meta (META.US), Netflix (NFLX.US), Tencent Holdings (00700), Alibaba (BABA.US), Bilibili (BILI.US), Hansoh Pharmaceutical (03692), CanSino Biologics-B (02162), Innovent Biologics (01801), and others [2]

Group 1: Economic Outlook - The U.S. economy is expected to maintain moderate growth in the coming year, supported by factors such as Federal Reserve interest rate cuts and AI investments [1] - The Hong Kong stock market is anticipated to shift from valuation-driven to profit growth-driven, with a projected earnings growth rate of 6% to 10% for the Hang Seng Index [1] Group 2: Market Dynamics - The valuation expansion in the Hong Kong market may weaken, but liquidity will remain supportive, leading to a new supply creating new demand [1] - The dual liquidity easing in both China and the U.S. is expected to increase foreign and southbound capital supply, translating into new demand for Hong Kong stocks [1] Group 3: Sector Analysis - The U.S. tech sector is expected to become more rational, with AI continuing to be a key driver, while the regulatory environment will favor mergers and acquisitions [2] - The domestic pharmaceutical and innovative drug sectors are likely to benefit from a resurgence in M&A activity from large multinational companies [2] - The automotive sector is projected to see flat or slightly declining sales, presenting opportunities to gradually accumulate stocks of companies with high earnings growth certainty [2] Group 4: Recommended Stocks - Top stock picks for the first quarter of next year include Alphabet (GOOGL.US), Meta (META.US), Netflix (NFLX.US), Tencent Holdings (00700), Alibaba (BABA.US), and others [3]

Summary of the Conference Call for 康诺亚 Company Overview - 康诺亚 is a leading company focused on autoimmune diseases, with core products including CM310 (思普曲帕单抗) and the next-generation dual antibody CM512 [2][3]. Key Products and Market Potential - **CM310 (思普曲帕单抗)**: - Recently included in the medical insurance directory, expected to see rapid market growth [2]. - Approved for three indications: adult moderate to severe atopic dermatitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis, with plans to expand to adolescents and children [2][3]. - Clinical trial results show a 52-week EASI75 response rate of 92.5% and EASI90 response rate of 77% in adult atopic dermatitis patients [4]. - In chronic rhinosinusitis, 90% of patients showed at least a 50% reduction in nasal polyps after 52 weeks [5]. - For seasonal allergic rhinitis, approximately 84% of patients experienced relief from nasal symptoms, and 94% from ocular symptoms [6]. - **CM512**: - A next-generation dual antibody targeting TSLP and IL-13, with a half-life of 70 days, allowing for dosing every three months [3][7]. - Phase I data shows EASI75 and EASI90 response rates of 58.3% and 41.7% respectively at 12 weeks, indicating competitive advantages over existing therapies [3][8]. - **CMG901 (Claudin 18.2 ADC)**: - Leading in the development for gastric and pancreatic cancer, with a phase III trial expected to complete by October 2026 [3][9]. - Early data shows a PFS of 4.8 months and OS of 11.8 months, indicating promising market potential [9]. Financial Projections - Revenue for CM310 is projected to grow rapidly, from approximately 300 million RMB in 2025 to about 750 million RMB in 2026 [10]. - Overall revenue estimates for 康诺亚 from 2025 to 2027 are 637 million, 764 million, and 480 million RMB, with year-on-year growth rates of 47%, 21%, and 94% respectively [10]. Valuation - Using a DCF model, 康诺亚's valuation is estimated at approximately 24.5 billion RMB, with a target price increase of 82%, leading to a buy rating [11]. Additional Insights - CM310 shows lower relapse rates and better safety and tolerability compared to Sanofi's Dupilumab, with a relapse rate of approximately 0.9% after 52 weeks [4]. - The company is positioned strongly in the market due to its innovative products and competitive advantages over existing therapies [7].

Overview of Autoimmune Diseases - Autoimmune diseases are characterized by the immune system's response to its own antigens, leading to tissue damage, with over 100 known types categorized into systemic and organ-specific diseases [2][7] - These diseases are often incurable and can be life-threatening, requiring long-term medication and incurring high treatment costs [10] Drug Development History - The traditional immunosuppressants have significant side effects, and the introduction of TNF-a inhibitors in 1998 marked the beginning of a targeted therapy era, leading to an explosion of innovative drugs [3][12] - The global autoimmune drug market reached $132.3 billion in 2022, with a projected compound annual growth rate (CAGR) of 27.2% from 2022 to 2030, potentially reaching nearly $20 billion in China by 2030 [3][18] Market Potential and Drug Trends - Approximately 7.6% to 9.4% of the global population suffers from autoimmune diseases, with some conditions affecting over 100 million people [3][16] - The global market for autoimmune drugs is dominated by biologics, which accounted for $96.4 billion (72.9%) of the total market in 2022, expected to grow to $176.7 billion by 2030 [18] Emerging Opportunities in Domestic Market - The domestic market for autoimmune drugs is still in its early stages, with a market size growing from $2 billion in 2018 to $2.9 billion in 2022, and expected to reach nearly $20 billion by 2030 [18] - The introduction of innovative domestic drugs is anticipated to accelerate post-2024, with several products expected to launch [31] Heavyweight Products in Autoimmune Drug Market - Autoimmune drugs are prevalent among the top 100 best-selling drugs globally, second only to oncology drugs, indicating a strong market presence [23][25] - Notable products include AbbVie's adalimumab, which has generated over $200 billion in sales from 2012 to 2022, and other drugs like risankizumab and dupilumab showing significant sales growth [25][27] Targeted Therapies and Innovations - The main domestic targets for autoimmune drugs include TNF-a, JAK inhibitors, and interleukins, with a focus on innovative therapies such as TYK2 inhibitors and bispecific antibodies [4][29] - The development of TYK2 inhibitors is gaining momentum due to their improved safety profile compared to earlier JAK inhibitors, with several products in advanced clinical stages [48][52] Conclusion - The autoimmune disease market presents substantial growth opportunities driven by increasing patient populations, innovative drug development, and a shift towards targeted therapies, particularly in the domestic market [3][18][31]

Core Insights - The 2025 National Medical Insurance (NMI) negotiation results were announced on December 7, highlighting a significant focus on innovative drugs, with 114 drugs added to the NMI list, including 50 Class I new drugs, achieving an overall negotiation success rate of 88% [1][3][4] - A notable shift in the negotiation approach emphasizes "clinical value" over "price," indicating a transition towards evaluating the real-world performance and patient benefits of drugs [1][2][5] Group 1: NMI Negotiation Results - The successful addition of 114 drugs to the NMI list includes 50 Class I innovative drugs, with a success rate of 88%, up from 76% in 2024 [3][4] - The inclusion of 19 drugs in the first version of the commercial insurance innovative drug directory reflects a growing integration between public and commercial insurance systems [1][3] - The focus on drugs with clear clinical value and unmet clinical needs is reshaping the evaluation criteria for NMI [4][5] Group 2: Policy Changes and Trends - Since the establishment of the NMI negotiation mechanism in 2019, the time frame for innovative drugs to be included in the NMI has significantly shortened from an average of 4-5 years to 1-2 years [2] - The new policy direction emphasizes "value-based purchasing," where the ability of drugs to improve disease outcomes and reduce patient burden is critical for NMI approval [2][5] - The integration of real-world data in NMI assessments is expected to enhance the evaluation of innovative drugs [2] Group 3: Impact on 2-Type Inflammatory Diseases - The focus on 2-type inflammatory diseases has gained attention, with significant patient populations affected by conditions like atopic dermatitis and chronic rhinosinusitis [6][7] - The introduction of the first domestic IL-4R α antibody drug into the NMI is seen as a pivotal moment for treatment accessibility in this area [7][8] - The drug's clinical data supports its efficacy in treating severe cases, providing a new affordable option for patients [8][9] Group 4: Commercialization of Domestic Innovative Drugs - The NMI negotiation is evolving from a perceived endpoint for innovative drug commercialization to a critical starting point for broader access and affordability [5][10] - The development of a comprehensive and sustainable "value realization pathway" for domestic innovative drugs is underway, reflecting improvements in research and clinical trial quality [11][12] - Companies like 康诺亚 are transitioning from single product breakthroughs to a systematic innovation approach, enhancing their competitive edge in the market [11][12] Group 5: Future Outlook - The acceleration of domestic innovative drug commercialization is expected, with more products entering the NMI and addressing complex diseases [13][14] - The integration of innovative drugs into the NMI is anticipated to enhance treatment accessibility and affordability for patients, marking a significant shift in China's pharmaceutical landscape [14]